|
 |
XopenexThis page contains recent news articles, when available, and an overview of Xopenex but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Xopenex (when available) Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis Mechanism Of Action: The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. News Articles on Vincristine Sepracor Announces Tender Offer for 0% Series B Convertible Senior ... - Oct 26, 2009 Lunesta, Xopenex, Xopenex HFA and Brovana are registered trademarks of Sepracor Inc. Omnaris and Alvesco are registered trademarks of Nycomed GmbH. ... Reuters Sepracor Inc. - SWOT Analysis - Aarkstore Enterprise - Nov 2, 2009 The increase was primarily due to strong sales performance of its marketed products such as Lunesta and Xopenex HFA during the year. ... PRMinds (press release) Magic Formula Buyouts and Bankruptcies 2009 - Nov 12, 2009 I was surprised because Sepracor was a company facing some big challenges, as 85% of sales come from Lunesta and Xopenex, two drugs that face strong branded ... Motley Fool Sepracor buyout completed; CEO Adams to receive up to $11M - Oct 21, 2009 ...the sleep aid Lunesta, will continue to be sold as a Sepracor (Nasdaq: SEPR) product, along with its asthma treatment Xopenex and other drugs. Mass High Tech Barr seeks to sell generic Xopenex - Jul 16, 2007 WOODCLIFF LAKE, NJ, July 16 (UPI) -- US generic firm Barr said Monday it is challenging the patent covering Sepracor's Xopenex to clear the way to market a ... United Press International Medicare Ruling Stings Sepracor - Jun 18, 2007 Reimbursement for Xopenex will decline because the federal Centers for Medicare ... For the quarter ended March 31, two types of Xopenex contributed $173 ... TheStreet.com - TheStreet.com (subscription) Sepracor profit misses estimates as Xopenex falls - Oct 28, 2008 NEW YORK, Oct 28 (Reuters) - Sepracor Inc (SEPR.O) posted a sharp decline in third-quarter profit on Tuesday, missing Wall Street estimates, ... Reuters Medicare Jitters Swat Sepracor - May 18, 2007 Shares of Sepracor(SEPR Quote) dropped sharply Friday after analysts warned that Medicare might reduce its reimbursement for the asthma drug Xopenex. ... TheStreet.com - TheStreet.com (subscription) Data for XOPENEX(R) Brand of Levalbuterol Presented at American … - Oct 23, 2006 MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of posters of clinical data from studies of XOPENEX HFA([R]) ... Free with registration - Business Wire - AccessMyLibrary.com Drug maker seeks to block generic version of Xopenex - Sep 8, 2005 Sepracor Inc. said a company is trying to make a generic version of its best-selling product, the asthma treatment Xopenex, and pledged to file a lawsuit to ... Boston Globe Sales Brisk at Sepracor | Robert Steyer News | Print Financial &... - Oct 25, 2005 During the third quarter Lunesta, which was launched in April, produced sales of $100.9 million, followed by the asthma drug Xopenex with $92.5 million. ... TheStreet.com - TheStreet.com (subscription) Sepracor profit badly misses views, shares slump - Jul 29, 2008 Combined sales of its Xopenex asthma drugs fell 14 percent to $99.5 million. Xopenex sales have been hurt by lower reimbursement rates from the US Medicare ... Reuters Sepracor results miss; stock plunges - Jul 27, 2007 Sales of respiratory drug Xopenex inhaled solution fell to $104.9 million ... "The outlook for Lunesta is difficult, the outlook for Xopenex is difficult, ... Reuters Sepracor Cuts Costs And Breathes Easier - May 1, 2008 ..."We would expect the shares to trade higher initially, as the Xopenex exclusivity situation is now better characterized, with Breath Limited now set to ... Forbes Sepracor posts 1st profit - Feb 1, 2006 Strong sales of Xopenex, an asthma treatment now available in more than one ... During 2005, Xopenex sales hit $440.5 million, most of that from sales of a ... $1.95 - Worcester Telegram Gazette - NewsBank Sepracor reports lower profit, announces layoffs - MarketWatch - Oct 30, 2007 However, sales of Xopenex HCL Inhalation Solution slid from $125.4 ... Another formulation of the drug, Xopenex HFA, saw sales leap 32% to $17.3 million. ... MarketWatch XOPENEX HFA(TM) Pediatric Data Presented at American College of … - Nov 7, 2005 Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of results of a four-week, multicenter, randomized, double-blind, placebo-controlled, ... RedOrbit Sepracor posts third quarter profit on strong sales - Oct 26, 2006 ...based drugmaker (Nasdaq: SEPR) attributed the growth to strong sales of the company's popular sleeping medication Lunesta and the asthma treatment Xopenex. ... Bizjournals.com FDA Approves Xopenex HFA (Levalbuterol Tartrate) Metered-Dose … - Mar 14, 2005 MARLBOROUGH, MA -- March 14, 2005 -- Sepracor Inc. (Nasdaq: SEPR) today announced that the US Food and Drug Administration (FDA) has approved its New Drug ... DG News Cowen maintains Sepracor's 'Outperform' rating on 1Q profit - May 1, 2008 Sepracor announced a settlement with Arrow Group over Xopenex Thursday. Meanwhile, the second and third quarters will be tougher for the company because of ... Boston Globe XOPENEX HFA(R) Data to Be Presented at American College of Allergy, … - Nov 7, 2006 Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol will be presented at the ... RedOrbit … bronchospasm - FDA Approves Sepracor's XOPENEX HFA(TM) Metered- … - Mar 13, 2005 Sepracor Inc (Nasdaq: SEPR) today announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for XOPENEX HFA(TM) ... Medical News Today - Medical News Today (press release) Sepracor Posts Loss on License Payment, Cuts Forecast - Feb 29, 2008 Xopenex sales fell 19 percent to $142.4 million. Medicare, the US health program for the elderly and disabled, cut Xopenex reimbursement rates in July, ... Bloomberg Sepracor gets FDA approval for Brovana - Oct 9, 2006 The other three include Lunesta, a treatment for insomnia, Xopenex HFA, an inhalation aerosol to treat bronchitis and Xopenex, a traditional inhalation ... Bizjournals.com No Sleep for Sepracor - Apr 25, 2005 ...fully" the company's near-term prospects for Lunesta and for Xopenex, an asthma medication, which accounted for $106.6 million in first-quarter sales. ... TheStreet.com - TheStreet.com (subscription) Adrian Adams named new CEO of Sepracor - May 15, 2007 Other than Lunesta, the company also sells bronchitis treatments Xopenex HFA and Xopenex. Sepracor announced last month that it would begin selling Brovana, ... Bizjournals.com Drug Costs Are Target of Long Beach Hospital Pharmacist; Melinda... - Jan 3, 2006 As they gathered in Memorial's medical library, they hoped to persuade Klein that Xopenex belonged on the hospital's formulary. Sterling urged Klein to try ... Pay-Per-View - Los Angeles Times - ProQuest Archiver Sepracor Shares Drop as Forecast Dips Below Estimates - Jan 31, 2007 Sepracor expects Lunesta and both forms of Xopenex to each bring in ... Lunesta sales were $566.8 million in 2006, and Xopenex brought in $591 million. ... Bloomberg Revenue Jumps at Sepracor | Biotech/Pharmaceuticals | Financial … - Jul 19, 2005 Lunesta, which was launched in April, recorded sales of $83.5 million for the second quarter, while the asthma treatment Xopenex contributed $83.2 million. TheStreet.com - TheStreet.com (subscription) Sepracor cuts 2007 view on competition, payments - Jul 27, 2007 O cut its 2007 earnings outlook on Friday amid generic competition for its sleep drug Lunesta and a reimbursement cut for its asthma drug Xopenex. ... Reuters XOPENEX HFA(R) Data Presented at American College of Allergy, … - Nov 13, 2006 Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol were presented at the American ... RedOrbit … Announces Final Settlement of XOPENEX(R) Inhalation Solution... - Jan 5, 2008 Sepracor Inc. (Nasdaq: SEPR) today announced that it has entered into a Settlement and License Agreement with Breath Limited (Breath), an Arrow Group ... Ad-Hoc-News - Ad-Hoc-News (Pressemitteilung) Xopenex HFA (Levalbuterol Tartrate) Metered-Dose Inhaler Now … - Dec 12, 2005 MARLBOROUGH, MA -- December 12, 2005 -- Sepracor Inc. today announced that Xopenex HFA™ (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane ... DG News Sepracor Names New COO - Mar 2, 2007 Sepracor makes the insomnia drug Lunesta and asthma drug Xopenex. The announcement came after the market closed Thursday. O'Shea, 57, had been president and ... TheStreet.com - TheStreet.com (subscription) XOPENEX(R) Brand of Levalbuterol Data to Be Presented at American … - Oct 18, 2006 Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol and XOPENEX(R) (levalbuterol ... Genetic Engineering News - Genetic Engineering News (press release) Real Story: Treasure Bath - May 18, 2007 ...big fall on speculation the Centers for Medicare and Medicaid Services could lower the selling price of its asthma drug Xopenex as soon as July 1. ... TheStreet.com - TheStreet.com (subscription) SEPR Said ANDA Filed for a Generic Version of its XOPENEX - Sep 7, 2005 Sepracor Inc. (Nasdaq: SEPR) said the FDA received an abbreviated new drug application from Breath Limited for a generic version of levalbuterol ... StreetInsider.com - StreetInsider.com (subscription) … and Development Agreement for XOPENEX(R)/Ipratropium Inhalation … - May 1, 2008 ..."This XOPENEX/ipratropium formulation should provide us with an exciting ... The XOPENEX/ipratropium combination, together with the recently acquired ... Genetic Engineering News - Genetic Engineering News (press release) Q2 2006 Sepracor Earnings Conference Call - Part 1. - Jul 21, 2006 The XOPENEX franchise remains strong with year-over-year growth of 40%. However, the uptake of XOPENEX HFA today has clearly been significantly below our ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Sepracor launches respiratory drug - Apr 11, 2007 ..."The launch of Brovana expands our respiratory portfolio of products, which includes Xopenex Inhalation Solution and Xopenex HFA metered-dose inhaler, ... Boston Globe Press Release: FDA Approves Sepracor's XOPENEX HFA(TM) Metered- … - Mar 11, 2005 FDA Approves Sepracor's XOPENEX HFA(TM) Metered-Dose Inhaler. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Sepracor Inc. Reports 2007 Fourth Quarter and Full-Year Results, … - Feb 29, 2008 Excluding XOPENEX Inhalation Solution revenues, the combined revenue growth for ... XOPENEX Inhalation Solution, which is a short-acting beta-agonist ... Lifescience-online Business | projo.com | The Providence Journal - Feb 18, 2005 The asthma drug Xopenex, introduced in 2000, was the company's first revenue-generating ... Sepracor, which also sells the Xopenex treatment for asthma, ... Providence Journal UnitedHealthcare lowers inhaler co-pay. - Apr 14, 2007 UnitedHealthcare's price drop applies to Xopenex HFA, an inhaler made by Massachusetts-based Sepracor. The insurer's co-payment for other brand-name ... Free with registration - Fort Worth Star-Telegram - AccessMyLibrary.com Drug Delivery; FDA approves XOPENEX HFA metered-dose inhaler - Apr 11, 2005 2005 APR 11 - (NewsRx.com) -- Sepracor, Inc., (SEPR) announced that the US Food and Drug Administration (FDA) has approved its new drug application (NDA) ... Pay-Per-View - Respiratory Therapeutics Week - Factiva, from Dow Jones … PROTEST ATTEMPT TO LOWER PAYMENT FOR XOPENEX - Jun 1, 2006 Pharmacists are claiming that a proposal made by Medicare durable medical equipment (DME) contractors to lower the reimbursement rate for the inhalation ... Pay-Per-View - Inside CMS - Factiva, from Dow Jones Article: Zofran, Xopenex HFA metered-dose inhaler.(New & Approved) - ... - May 1, 2005 Zofran, Xopenex HFA metered-dose inhaler.(New & Approved) ... find Pediatric News articles. Zofran (ondansetron injection, GlaxoSmithKline Inc.) The Food ... Pay-Per-View - Pediatric News - HighBeam Research Levalbuterol tartrate (Xopenex HFA) for the treatment of bronchospasm.... - Jan 15, 2007 Levalbuterol tartrate (Xopenex hFa) is a [beta.sub.2]-agonist, ... Xopenex HFA (levalbuterol tartrate) inhalation aerosol [prescribing information]. ... Free with registration - American Family Physician - AccessMyLibrary.com Xopenex available.(antiasthmatic agents' availability)(Brief Article) - Jan 16, 2006 Xopenex HFA inhalation aerosol is now available in pharmacies across the nation. The Sepracor Inc. product is indicated for patients with symptoms of asthma ... Free with registration - Chain Drug Review - AccessMyLibrary.com Zofran, Xopenex HFA inhaler.(New & Approved) - May 15, 2005 The Food and Drug Administration approved two new indications for Zofran (ondansetron) injection: prevention of nausea and vomiting associated with general ... Free with registration - Family Practice News - AccessMyLibrary.com Sepracor Sues Barr Over Generic Xopenex Plans - Jul 25, 2007 Sepracor initiated a lawsuit against Barr Laboratories after Barr filed an abbreviated new drug application (ANDA) seeking approval for a generic version of ... FDA news - FDA news (subscription) Xopenex HFA inhaler available.(Products) - Feb 1, 2006 Xopenex HFA (levalbuterol tartrate) inhalation aerosol is now available. The short-acting [beta]-agonist is indicated for the treatment or prevention of ... Free with registration - Family Practice News - AccessMyLibrary.com Drug Delivery; FDA approves XOPENEX HFA metered-dose inhaler - Apr 17, 2005 2005 APR 17 - (NewsRx.com) -- Sepracor, Inc., (SEPR) announced that the US Food and Drug Administration (FDA) has approved its new drug application (NDA) ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Sepracor, Inc. FDA approves XOPENEX HFA metered-dose inhaler - Apr 13, 2005 2005 APR 13 - (NewsRx.com) -- Sepracor, Inc., (SEPR) announced that the US Food and Drug Administration (FDA) has approved its new drug application (NDA) ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Q4 2006 Sepracor Earnings Conference Call - Part 1. - Jan 3, 2007 Jim O'Shea will review the progress of Lunesta, Xopenex and Brovana brands and ... Xopenex UDV revenues were $179.9 million, Xopenex HFA brand levalbuteral ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Xopenex HFA inhaler available.(PRODUCTS) | Article from Internal … - Mar 1, 2006 Xopenex HFA inhaler available.(PRODUCTS) ... find Internal Medicine News articles. Xopenex HFA (levalbuterol tartrate) inhalation aerosol is now available. Pay-Per-View - Internal Medicine News - HighBeam Research Lower costs help Sepracor beat profit forecast - May 1, 2008 O) on Thursday posted better-than-expected first-quarter profit as lower costs helped offset declines in sales of its Lunesta insomnia treatment and Xopenex ... Reuters FDA Approvals: Temodar, LR3001, Xopenex HFA - Mar 17, 2005 March 17, 2005 — The US Food and Drug Administration (FDA) has approved a new indication for temozolomide, allowing its use in the first-line treatment of ... Medscape Sepracor Submits LUNIVIA(R) (LUNESTA(R) in US) Marketing … - Jul 27, 2007 Brovana is a trademark and Lunesta, Lunivia, Xopenex and Xopenex HFA are registered trademarks of Sepracor Inc. Effexor XR is a registered trademark of ... Free with registration - Business Wire - AccessMyLibrary.com Levalbuterol tartrate (Xopenex HFA) for the treatment of bronchospasm.... - Jan 15, 2007 Levalbuterol tartrate (Xopenex hFa) is a [beta.sub.2]-agonist, hydrofluoroalkane inhalation aerosol labeled for the treatment or prevention of bronchospasm ... $4.95 - American Family Physician - ECNext Sepracor Announces Fourth Quarter and Full Year 2005 Results; … - Jan 31, 2006 In December, we expanded our XOPENEX franchise with the launch of XOPENEX HFA, ... In 2005, Sepracor presented XOPENEX Inhalation Solution clinical data at ... RedOrbit Xopenex ready for market.(Branded Drugs)(Brief Article) - Apr 18, 2005 The FDA has approved Sepracor Inc.'s Xopenex HFA, a metered-dose inhaler. The innovative product is for the treatment or prevention of bronchospasm in ... Free with registration - Chain Drug Review - AccessMyLibrary.com Sepracor takes issue with CMS "bundling" of Xopenex. - Jun 25, 2007 Sepracor takes issue with CMS "bundling" of Xopenex. US drugmaker Sepracor says that the Centers for Medicare and Medicaid Services (CMS) has issued its ... $9.94 - Pharma Marketletter - Alacra Store Article: Sepracor Wins FDA Approval for HFA Asthma Inhaler. - Ozone … - Mar 16, 2005 ..."We are extremely pleased that the XOPENEX HFA MDI received first-cycle approval ... It remains our target to launch XOPENEX HFA around the end of the year, ... Pay-Per-View - Ozone Depletion Today - HighBeam Research Zofran, Xopenex HFA inhaler.(New & Approved) | Article from Family … - May 15, 2005 Zofran, Xopenex HFA inhaler.(New & Approved) ... find Family Practice News articles. Zofran (ondansetron injection, GlaxoSmithKline Inc.) The Food and Drug ... Pay-Per-View - Family Practice News - HighBeam Research Sepracor Inc. Reports Second Quarter 2008 Results - Jul 29, 2008 The reduction of XOPENEX Inhalation Solution revenues for the second quarter 2008 ... XOPENEX HFA(R) brand levalbuterol tartrate Inhalation Aerosol, ... Genetic Engineering News - Genetic Engineering News (press release) Xopenex available. - Jan 16, 2006 Xopenex HFA inhalation aerosol is now available in pharmacies across the nation. The Sepracor Inc. product is indicated for patients with symptoms of asthma ... $9.94 - Chain Drug Review - Alacra Store Article: Xopenex ready for market.(Branded Drugs)(Brief Article) -... - Apr 18, 2005 Xopenex ready for market.(Branded Drugs)(Brief Article) ... find Chain Drug Review articles. The FDA has approved Sepracor Inc.'s Xopenex HFA, ... Pay-Per-View - Chain Drug Review - HighBeam Research Xopenex available. - Jan 16, 2006 Xopenex HFA inhalation aerosol is now available in pharmacies across the nation. The Sepracor Inc. product is indicated for patients with symptoms of asthma ... $9.94 - Chain Drug Review - Alacra Store Xopenex ready for market. - Apr 18, 2005 The FDA has approved Sepracor Inc.'s Xopenex HFA, a metered-dose inhaler. The innovative product is for the treatment or prevention of bronchospasm in ... $9.94 - Chain Drug Review - Alacra Store SEPRACORE REPORTS NET INCOME OF $11.3 MIL FOR 2ND QTR … - Sep 1, 2006 XOPENEX(R) brand levalbuterol HCl Inhalation Solution - Marketed through Sepracor's ... XOPENEX is available for use in a nebulizer, which is a machine that ... Entrepreneur Sepracor at Cowen and Company 7th Annual Global Health Care … - Nov 8, 2006 We've been selling Xopenex inhalation solution since 1999. ... This was primarily driven by Lunesta and the Xopenex [inaudible]. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q3 2005 Sepracor Earnings Conference Call - Part 1. - Oct 2, 2005 Both of the Company's major products, Xopenex and Lunesta, experienced robust ... That's $92.5 million for sales from Xopenex brand levalbuterol inhalation ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Xopenex HFA inhaler available.(PRODUCTS) - Mar 1, 2006 Xopenex HFA (levalbuterol tartrate) inhalation aerosol is now available. The short-acting [beta]-agonist is indicated for the treatment or prevention of ... Pay-Per-View - Internal Medicine News - Factiva, from Dow Jones FDA Approves Sepracor's Xopenex HFA Metered-Dose Inhaler - Mar 22, 2005 The FDA has approved Sepracor's new drug application for Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Medicare Reimbursement for Xopenex Soars - Mar 21, 2005 BALTIMORE--Respiratory drug providers found that Medicare fees for Xopenex will shoot up 33 cents a dose, as CMS released its second-quarter Part B drug ... Pay-Per-View - Primedia Insight - Factiva, from Dow Jones Article: SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 … - Sep 1, 2005 Business Wire; June 18, 2007 ; 700+ words ... ... dose for the 1.25 mg dose of XOPENEX Inhalation Solution, which is the dose of XOPENEX Inhalation Solution ... Pay-Per-View - Biotech Financial Reports - HighBeam Research Levalbuterol Tartrate Data Presented at American College of Allergy, ... - Nov 28, 2006 Xopenex HFA is a hydrofluoroalkane MDI, which is a portable, ... Xopenex HFA is indicated for treatment or prevention of bronchospasm in adults, ... DG News cjp2007's SharePosts - Sep 6, 2007 I am so tired of taking asthma medications (Advair, Allegra, Xopenex, Flonase). I particularly would like to stop the Advair. I seem to have alot of side ... HealthCentral.com LETTERS; Hospital Cost Cutting Could Trigger Lawsuits - Jan 22, 2006 Case in point: One of the drugs that pharmacist Melinda Klein successfully removed from her hospital's formulary is Xopenex. Our 4- year-old son has an ... Pay-Per-View - Los Angeles Times - ProQuest Archiver The Higher Cost of Breathing - May 12, 2006 The company says that Xopenex, available in an HFA inhaler since December, is an improved, safer version of albuterol — although The Medical Letter, ... New York Times Press Release: NEW MEDICATION HELPS RELIEVE SYMPTOMS … - Dec 13, 2005 ..."Xopenex HFA inhaler signals an advance in treatment and it's exciting to finally ... We are extremely pleased that the XOPENEX HFA MDI received first-cycle ... Pay-Per-View - PR Newswire - HighBeam Research SEPR - Sepracor Inc Company Profile - CNNMoney.com - Dec 12, 2008 Sepracor, LUNESTA, XOPENEX, XOPENEX HFA and BROVANA are registered trademarks of the company. Officers: Adrian Adams, Director/President/CEO Mark Iwicki, ... CNNMoney.com Sepracor Inc - Jun 19, 2006 The Xopenex inhalation solution is an improved version of generic ... In December 2005, the company launched Xopenex HFA (levalbuterol tartrate) inhalation ... $35.00 - Stock Reports - Standard & Poor's Sepracor Announces Second Quarter 2005 Operating Results - Jul 19, 2005 XOPENEX(R) brand levalbuterol HCl - Marketed through Sepracor's sales force, ... XOPENEX is available for use in a nebulizer at 0.31 mg and 0.63 mg dosage ... RedOrbit Sepracor Inc. Announces Second Quarter 2007 Results and Significant … - Jul 27, 2007 XOPENEX([R]) brand levalbuterol HCl Inhalation Solution, ... XOPENEX HFA([R]) brand levalbuterol tartrate Inhalation Aerosol, a metered-dose inhaler (MDI) ... Free with registration - Business Wire - AccessMyLibrary.com SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 MILLION. - Sep 1, 2005 XOPENEX(R) brand levalbuterol HCl - Marketed through Sepracor's sales force, ... XOPENEX is available for use in a nebulizer at 0.31 mg and 0.63 mg dosage ... Entrepreneur Current Research on Sepracor, Inc. - May 21, 2007 Its marketed products include asthma drug Xopenex and insomnia therapy Lunesta. ... Xopenex is an altered form of the generic drug albuterol. ... $4.95 - M2 Presswire - ECNext Q4 2006 Sepracor Earnings Conference Call - Final. - Jan 31, 2007 Jim O'Shea will review the progress of Lunesta, Xopenex and Brovana brands and ... Xopenex UDV revenues were $179.9 million, Xopenex HFA brand levalbuteral ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Sepracor's Lunesta Could Drive Stock Upside - Sep 23, 2005 ..."Xopenex HFA could surprise. Sepracor very successfully launched the Xopenex nebulizer and will bring its marketing prowess to the HFA market," said Goldman ... Forbes Starks v. Astrue, No. 2:07cv539-WC (MDAla. 04/18/2008) - Apr 18, 2008 Xopenex and Albuterol are bronchodilators. See Physicians' Desk Reference at 102, 212 (2008). The medical evidence shows the claimant received prescriptions ... $2.95 - U.S. District Court, Middle District of... - VersusLaw CHEST: Cutting Drug Dose by Enhancing Nebulizers in COPD Seen Safe … - Nov 1, 2006 First, the clinicians at Crouse Hospital in Syracuse, NY, replaced albuterol with Xopenex (levalbuterol) because patients were having breakthrough bouts of ... MedPage Today Press Release: Sepracor Announces First Quarter 2005 Operating … - Apr 25, 2005 XOPENEX Inhalation Solution is a short-acting bronchodilator indicated for ... XOPENEX Inhalation Solution is available for use in a nebulizer at 0.31 mg ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Sepracor Announces Fourth Quarter and Full Year 2004 … - Jan 27, 2005 XOPENEX is a short-acting bronchodilator indicated for the treatment or ... XOPENEX is available for use in a nebulizer at 0.31 mg and 0.63 mg dosage ... Pay-Per-View - PR Newswire - HighBeam Research Sepracor Announces Fourth Quarter and Full Year 2006 Results.( … - Jan 31, 2007 ...million (XOPENEX Inhalation Solution revenues were $146.0 million, XOPENEX HFA revenues were $12.0 million and LUNESTA revenues were $144.9 million), ... $4.95 - Business Wire - ECNext Sepracor's profit drops 33 percent - Marlboro drugmaker cuts 300 jobs... - Oct 31, 2007 But sales of the most popular version of Xopenex dropped to $94.4 million from $125.4 ... The company's results, despite the decline in Xopenex sales, ... $1.95 - Worcester Telegram Gazette - NewsBank Medicare contractors suspend Sepracor pricing cuts - Jun 13, 2008 Sales of Xopenex, one of Sepracor's flagship drugs that is also used for chronic obstructive pulmonary disease, were $160 million in the first quarter of ... Reuters India Sanderson Group PLC acquires Retail Business Solutions - Deal … - Sep 15, 2007 Analyst Greg Gilbert…the performance of XOPENEX Inhalation Solution in the first quarter given…XOPENEX and generic albuterol Inhalation Solution products, ... Pay-Per-View - deals - Alacra Store NEW MEDICATION HELPS RELIEVE SYMPTOMS ASSOCIATED WITH … - Dec 13, 2005 XOPENEX.COM THIS IS DANIELLE ADDAIR REPORTING. Important Safety Information. Xopenex HFA is contraindicated in patients with a history of hypersensitivity ... $4.95 - PR Newswire - ECNext Generic name: Levalbuterol hydrochloride - Dec 1, 2005 Xopenex is a "bronchodilator." It works by relaxing the muscles in the walls of the lungs' ... If your prescribed dosage of Xopenex does not provide relief, ... Free with registration - PDR Family Guide to Prescription Drugs - AccessMyLibrary.com Q4 2005 Sepracor Earnings Conference Call - Part 1. - Jan 3, 2006 Xopenex brand Inhalation Solution revenues were $146.0 million. Xopenex HFA brand, levalbuterol, was 12.0 million and Lunesta brand eszopiclone revenues ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Sepracor profits from insomnia, asthma drugs - Feb 23, 2007 With the asthma treatment Xopenex, launched in 2000, Sepracor started ... Last year, Xopenex sales totaled $596 million, and Lunesta sales hit $566.8 ... $1.95 - Worcester Telegram Gazette - NewsBank Gainer: Citizens National Bancorp Inc. $119.00 +$11.00 (Volume of 600... - Mar 12, 2005 MARLBORO - Sepracor Inc. said yesterday the Food and Drug Administration has approved its metered-dose inhaler version of the asthma drug Xopenex for adults ... $1.95 - Worcester Telegram Gazette - NewsBank Business & Finance; Science-based pharmaceutical company reports Q4, … - Feb 21, 2005 Xopenex brand levalbuterol HCl inhalation solution is marketed through Sepracor. Xopenex is a short-acting bronchodilator indicated for the treatment or ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Brand Names/Synonyms: Xopenex is also known by the following brand names and/or synonymsIndole alkaloid; LCR; Leurocristine; Onco TCS; Oncovin; VCR; VIN; Vincasar PFS; Vincrex; Vincristina [DCIT]; Vincristine; Vincristine Sulfate; Vincristine Sulfate PFS; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; 22-Oxovincaleukoblastine; EINECS 200-318-1; Oncovin (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Z-D-Val-Lys(Z)-OH Drug Category: Xopenex is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01CA02 Dosage Forms: LIQUID; SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |